Cutaneous side-effects of kinase inhibitors and blocking antibodies
Top Cited Papers
- 1 July 2005
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 6 (7), 491-500
- https://doi.org/10.1016/s1470-2045(05)70243-6
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancerAnnals of Oncology, 2005
- Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Proteomic identification of 14-3-3 sigma as a common component of the androgen receptor and the epidermal growth factor receptor signaling pathways of the human prostate epithelial cell line M12Oncogene, 2004
- Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumoursBritish Journal of Dermatology, 2004
- Doxycycline Is Anti-Inflammatory and Inhibits Staphylococcal Exotoxin-Induced Cytokines and ChemokinesAntimicrobial Agents and Chemotherapy, 2003
- Imatinib treatment: Specific issues related to safety, fertility, and pregnancySeminars in Hematology, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Cerebral oedema as a possible complication of treatment with imatinibThe Lancet, 2002
- Inflammatory Skin Diseases, T Cells, and Immune SurveillanceNew England Journal of Medicine, 1999
- The microscopic appearance of waved-2 mouse hairsGenetics Research, 1971